<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Des Devel Ther</journal-id><journal-id journal-id-type="iso-abbrev">Drug Des Devel Ther</journal-id><journal-id journal-id-type="publisher-id">Drug Design, Development and Therapy</journal-id><journal-title-group><journal-title>Drug Design, Development and Therapy</journal-title></journal-title-group><issn pub-type="epub">1177-8881</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28138220</article-id><article-id pub-id-type="pmc">5241128</article-id><article-id pub-id-type="doi">10.2147/DDDT.S128869</article-id><article-id pub-id-type="publisher-id">dddt-11-175</article-id><article-categories><subj-group subj-group-type="heading"><subject>Corrigendum</subject></subj-group></article-categories><title-group><article-title>Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials [Corrigendum]</article-title></title-group><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>11</day><month>1</month><year>2017</year></pub-date><volume>11</volume><fpage>175</fpage><lpage>175</lpage><permissions><copyright-statement>&#x000a9; 2017 Toussirot et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2017</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions></article-meta></front><body><p>Toussirot E, Vauchy C, Binda D, Michel F. <italic>Drug Des Devel Ther</italic>. 2016;10:<related-article related-article-type="corrected-article" id="d35e61" vol="10" page="2087" ext-link-type="pmc">2087&#x02013;2094</related-article>.</p><p>On page 2089, a column heading in <xref ref-type="table" rid="t1-dddt-11-175">Table 1</xref> was incorrectly presented. The last column heading was presented as &#x0201c;Golimumab 60 mg&#x0201d;, whereas this should have been presented as &#x0201c;Golimumab 100 mg&#x0201d; as shown below:</p></body><floats-group><table-wrap id="t1-dddt-11-175" position="float"><label>Table 1</label><caption><p>Proportion of ASAS20 responders in the GO-RAISE and GO-AHEAD studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Study</th><th valign="top" align="left" rowspan="1" colspan="1">Placebo</th><th valign="top" align="left" rowspan="1" colspan="1">Golimumab 50 mg</th><th valign="top" align="left" rowspan="1" colspan="1">Golimumab 100 mg</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">GO-RAISE, primary end point at Week 14<sup>15</sup></td><td valign="top" align="left" rowspan="1" colspan="1">21.8</td><td valign="top" align="left" rowspan="1" colspan="1">59.4</td><td valign="top" align="left" rowspan="1" colspan="1">60</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO-RAISE, 2 years<sup>17</sup></td><td valign="top" align="left" rowspan="1" colspan="1">38.5</td><td valign="top" align="left" rowspan="1" colspan="1">60.1</td><td valign="top" align="left" rowspan="1" colspan="1">71.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GO-AHEAD, primary end point at Week 16<sup>16</sup></td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">71.1</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-dddt-11-175"><p><bold>Abbreviations:</bold> ASAS, Assessment of SpondyloArthritis international Society; NA, not available.</p></fn></table-wrap-foot></table-wrap></floats-group></article>